Internal Medicine

Nearly half of patients not in clinical remission achieved de novo clinical remission after 1 year in the maintenance study.

Data from a secondary analysis of the PREDICT 1 trial provides insight into the effects of sleep habits on postprandial glucose control among a cohort of healthy individuals.

The approval of daratumumab and hyaluronidase-fihj plus carfilzomib and dexamethasone is for treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

Endoscopies can be costly, invasive, and time-consuming as a way to assess disease active and infliximab efficacy in IBD.

A NDM cohort in Israel found those with TNDM were taller and heavier compared to PNDM, while chronic diabetes complications developed in patients with long-standing NDM.

The ergonomic device for the treatment of diabetes is the only insulin patch pump for closed loop integration able to be used with standard, pre-filled pump cartridges.

VX-880 stem cell-derived therapy demonstrated restoration of insulin production and was generally well-tolerated in T1D treatment.

More global studies on the prevalence of celiac disease are needed outside of the US and Europe.

The overall risk of SARS-CoV-2 breakthrough infection was 15.4% in the multiple myeloma population and 3.9% in the noncancer population.

From 1976 to 2018, data show the prevalence of obesity in the United States increased from 6.2% to 32.7%.

Diagnosing patients with classic GERD symptoms such as heartburn and regurgitation call for an 8-week trial of empiric proton pump inhibitors once daily prior to a meal.

In this video interview, Titilope Fasipe shares a summary of her plenary presentation on sickle cell disease from the National Organization for Rare Disease summit.

Dr. Leng discusses the progression of dry AMD patients in the IRIS registry from early stages to potential GA, as well as the benefit in narrowing the clinical definition of intermediate dry AMD.

At AAO 2021, Dr. Sahel discussed the findings of the PIONEER trial on the combination of an optogenetics device and gene therapy in treatment of RP.

Investigators found that using virtual reality to reduce pain levels during operational hsyteroscopy was not effective.

Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results

Bentracimab achieved the predetermined primary endpoint of immediate and sustained reversal of the antiplatelet effects of ticagrelor in the REVERSE-IT trial.

Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.

Hydroxyurea has been on the market for decades and yet it's underutilized as a treatment for sickle cell disease.

Dr. Khanani highlights data from MERLIN showing noninferiority of brolucizumab to aflibercept in nAMD treatment, but a higher rate of intraocular inflammation.

Treatment with statins, nitrates, dihydropyridines, verapamil, and proton-pump inhibitors were predictors of death or ischemic events for patients in the HGFR group.

Dr. Sheth discusses the data from the late-breaking Phase 2B ALTISSIMO study.

Ropeginterferon Alfa-2b-NJFT (Besremi) is approved by the FDA for the treatment of polycythemia vera regardless of a patient's treatment history.

Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.

Dr. Regillo discusses the efficacy and durability of faricimab for wet AMD treatment in TENAYA and LUCERNE, showing noninferiority to aflibercept.